New nanoparticle treatment for peritoneal ovarian cancer
Nanoparticle formulation of Mediator kinase inhibitor for the treatment of peritoneal ovarian cancer
['FUNDING_OTHER'] · SENEX BIOTECHNOLOGY, INC. · NIH-11066897
This study is testing a new way to deliver a cancer-fighting drug directly into the abdomen to help treat metastatic ovarian cancer, aiming to make the treatment more effective for patients facing this tough condition.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SENEX BIOTECHNOLOGY, INC. (nih funded) |
| Locations | 1 site (COLUMBIA, UNITED STATES) |
| Trial ID | NIH-11066897 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel nanoparticle formulation of a Mediator kinase inhibitor to treat metastatic ovarian cancer, particularly in the peritoneal cavity. The approach aims to enhance the effectiveness of the drug SNX631-6 by delivering it directly into the abdominal cavity through intraperitoneal (IP) administration, which could improve its absorption and efficacy compared to oral delivery. The study investigates the drug's ability to inhibit tumor growth and aims to provide a more targeted treatment option for patients with this challenging cancer type.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic ovarian cancer localized to the peritoneal cavity who have not responded adequately to conventional therapies.
Not a fit: Patients with early-stage ovarian cancer or those whose cancer has metastasized beyond the peritoneal cavity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for patients suffering from peritoneal ovarian cancer, potentially improving survival rates and quality of life.
How similar studies have performed: While the use of nanoparticle formulations in cancer treatment is a growing field, this specific approach targeting Mediator kinases in peritoneal ovarian cancer is novel and has not been extensively tested in prior studies.
Where this research is happening
COLUMBIA, UNITED STATES
- SENEX BIOTECHNOLOGY, INC. — COLUMBIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHEN, MENGQIAN — SENEX BIOTECHNOLOGY, INC.
- Study coordinator: CHEN, MENGQIAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, anti-cancer drug, anti-cancer therapy